AAPG
AAPGHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeHeadquartered within the healthcare sector, AAPG focuses on Biotechnology services and products. Ascentage Pharma Group International, a clinical-stage biotechnology company, develops therapies for cancers, chronic hepatitis B virus (HBV), and age-related diseases in Mainland China. With a market capitalization of $1.86B, it sits in small-cap territory. The company's primary product candidate is HQP1351, a BCR-ABL inhibitor targeting BCR-ABL1 mutants, including those with the T315I mutation.
Market Cap
$1.86B
Beta
0.72
P/E (TTM)
—
P/E (Fwd)
-16.64
EPS (TTM)
$-2.05
EPS (Fwd)
$-1.20
ROE
-154.6%
ROA
-23.0%
Cash
$2.47B
Total Debt
$1.98B
Free CF
-$942.6M
52W Change
-18.5%
Annual Financials
Cash vs Debt
The balance sheet looks solid with $2.47B in cash comfortably exceeding the $1.98B debt load. A net cash position generally provides financial flexibility during uncertain economic periods. The company is burning cash, with free cash flow at -$942.6M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. ROE of -154.6% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Revenue has grown from $209.7M (2022) to $574.1M (2025), reflecting a 174% increase over the period.
The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing AAPG.